Joerg Lehmann
@joerglehmann.bsky.social
Which failures do patient-specific quality assurance (PSQA) systems need to catch?
First publication of an international collaboration systematically addressing PSQA in Radiation Therapy.
dx.doi.org/10.1002/mp.1...
First publication of an international collaboration systematically addressing PSQA in Radiation Therapy.
dx.doi.org/10.1002/mp.1...
<em>Medical Physics</em> | AAPM Journal | Wiley Online Library
Background The Joint AAPM-ESTRO TG-360 is developing a quantitative framework to evaluate treatment verification systems used for patient-specific quality assurance (PSQA). A subgroup was commission...
dx.doi.org
January 5, 2025 at 12:52 PM
Which failures do patient-specific quality assurance (PSQA) systems need to catch?
First publication of an international collaboration systematically addressing PSQA in Radiation Therapy.
dx.doi.org/10.1002/mp.1...
First publication of an international collaboration systematically addressing PSQA in Radiation Therapy.
dx.doi.org/10.1002/mp.1...
Reposted by Joerg Lehmann
Controversial paper just out in the @thelancet.bsky.social
Study of population-health impact of funding new drugs recommended by the NHS England’s NICE body during 2000–20:
➡️New drugs resulted cost £75·1 billion
➡️net loss of approximately 1·25 million QALYs
www.thelancet.com/journals/lan...
Study of population-health impact of funding new drugs recommended by the NHS England’s NICE body during 2000–20:
➡️New drugs resulted cost £75·1 billion
➡️net loss of approximately 1·25 million QALYs
www.thelancet.com/journals/lan...
Population-health impact of new drugs recommended by the National Institute for Health and Care Excellence in England during 2000–20: a retrospective analysis
During 2000–20, NHS coverage of new drugs displaced more population health than it generated. Our results highlight the inherent trade-offs between individuals who directly benefit from new drugs and those who forgo health due to the reallocation of resources towards new drugs.
www.thelancet.com
January 3, 2025 at 3:03 PM
Controversial paper just out in the @thelancet.bsky.social
Study of population-health impact of funding new drugs recommended by the NHS England’s NICE body during 2000–20:
➡️New drugs resulted cost £75·1 billion
➡️net loss of approximately 1·25 million QALYs
www.thelancet.com/journals/lan...
Study of population-health impact of funding new drugs recommended by the NHS England’s NICE body during 2000–20:
➡️New drugs resulted cost £75·1 billion
➡️net loss of approximately 1·25 million QALYs
www.thelancet.com/journals/lan...
